The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic Development | Zendy

Manica Balasegaram | Zendy; Laura J. V. Piddock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic Development

Author(s) -

Manica Balasegaram,

Laura J. V. Piddock

Publication year - 2020

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.0c00101

Subject(s) - general partnership , antibiotics , drug development , intensive care medicine , medicine , sepsis , business , immunology , drug , microbiology and biotechnology , biology , finance , psychiatry

The Global Antibiotic Research and Development Partnership (GARDP) brings together public and private partners to accelerate the development and global availability of new antibiotics to treat the most challenging drug-resistant bacterial infections. Established in 2016, GARDP's recently launched strategy sets out its ambitious aim to deliver five new treatments by 2025, focusing on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research